BLKB · Blackbaud, Inc. · Stock research

Current Thesis

Blackbaud is no longer being priced as a growth-software name. The pipeline's adjusted bars put the 52-week high at $70.17; stockanalysis.com shows a 52-week low of $25.58 as of 2026-08-07. What is being re-underwritten now is a cash-return and share-count-shrinkage story, and the 2026-07-29 Q2 print supplied the evidence for it: GAAP revenue $290.6M (+3.0%), non-GAAP organic revenue +3.0%, recurring revenue $285.3M (+3.3%) at 98.2% of total, adjusted EPS $1.33 versus a $1.28 consensus, and FY2026 guidance affirmed at $1.173–$1.179B revenue and $5.15–$5.25 adjusted EPS — with management stating it expects to finish in the upper half of the revenue, adjusted EBITDA, non-GAAP EPS and free-cash-flow ranges, and EPS and FCF at the high end.

The capital-return leg is the load-bearing part. As of 2026-06-30 roughly $850M remained under the repurchase program that was expanded and reauthorized in December 2025; the company had repurchased just over 6% of shares year-to-date and has reduced shares outstanding by approximately 15% since Q4 2023. Shares outstanding stood at 44.72M against a $2.05B market cap and an 8.16 forward P/E (stockanalysis.com, 2026-08-07).

The complication is the tape. The 2026-08-07 close of $45.87 carried RSI(14) at 80.1 and a 22.3% three-month gain while still sitting 34.6% below the 52-week high. Nothing on the company's own calendar resolves anything before the Q3 print, which had not been scheduled as of 2026-08-08.

Bullish and bearish views on Blackbaud, Inc.

The model's bull view on Blackbaud, Inc. (BLKB), in brief: Q2 FY26 (2026-07-29): GAAP revenue $290.6M, +3.0%; non-GAAP organic revenue +3.0%; GAAP recurring revenue $285.3M, +3.3%, equal to 98.2% of total revenue. The bear view: The top line missed: revenue $290.597M against $292.303M consensus on 2026-07-29. Both cases follow in full.

Bull Case

• Q2 FY26 (2026-07-29): GAAP revenue $290.6M, +3.0%; non-GAAP organic revenue +3.0%; GAAP recurring revenue $285.3M, +3.3%, equal to 98.2% of total revenue. Adjusted EPS $1.33 against $1.28 consensus.
• Guide affirmed with a positive skew (2026-07-29): FY2026 revenue $1.173–$1.179B (consensus $1.176B) and adjusted EPS $5.15–$5.25 (consensus $5.19), plus explicit commentary that the company expects the upper half of its ranges, with EPS and free cash flow at the high end.
• The issuer is the marginal buyer: ~$850M remaining under the repurchase authorization at 2026-06-30, just over 6% of shares retired year-to-date, ~15% fewer shares outstanding than Q4 2023. Set that $850M figure beside the $2.05B market cap at the 2026-08-07 close.
• Multiple: forward P/E 8.16, trailing P/E 14.27, TTM EPS $3.22, TTM net income $150.68M on $1.15B TTM revenue (stockanalysis.com, 2026-08-07). Consensus analyst target $53.40 versus the $45.87 close.
• Revenue quality: at 98.2% recurring in Q2, the free cash flow funding the buyback is subscription-derived rather than order-book dependent.
• Sponsor precedent (historical, not live): Blackbaud confirmed receipt of an unsolicited, non-binding all-cash proposal from Clearlake Capital at $80.00 per share on 2024-04-15, which the board reviewed and rejected; a limited-duration shareholder rights plan followed in 2024. That is a two-year-old data point about how a financial buyer once priced the asset, and no current bid is in evidence.

Bear Case

• The top line missed: revenue $290.597M against $292.303M consensus on 2026-07-29. The beat was on the EPS line, which a shrinking denominator flatters.
• One quarter is not a re-acceleration: TTM revenue growth was 0.7% as of 2026-08-07 (stockanalysis.com) against the 3.0% Q2 organic print. A single quarter establishes nothing about the trend.
• The sell-side has not converted. Stifel maintained Hold and cut its target to $30 on 2026-07-10. Evercore ISI maintained In-Line and raised its target to $48 on 2026-07-30. The 2026-08-07 close of $45.87 already trades well above one published target and within a few dollars of the other; the recent rating actions were target adjustments without a rating change.
• Overhead supply: the name is 34.6% below the $70.17 adjusted 52-week high. Every level between the current price and that high was distribution for holders who bought higher in the prior twelve months.
• Buyback dependency cuts both ways: with 44.72M shares outstanding, EPS growth leans on repurchase pace. A free-cash-flow shortfall would hit both the numerator and the pace of denominator reduction in the same quarter.
• Leverage unquantified here: the sources reviewed for this note do not give a current net-debt figure. Any assessment of how much of the $850M authorization is fundable from cash flow versus balance sheet requires the Q2 10-Q.

Setup & Price Structure

• Price basis: $45.87 close, 2026-08-07. RSI(14) 80.1. Three-month return +22.3%. Distance from the $70.17 52-week high: -34.6%. 52-week low $25.58 (stockanalysis.com, 2026-08-07).
• Life-cycle: ACCELERATING. What dates it: the 2026-07-29 Q2 beat-and-affirm, the 2026-07-30 Evercore target raise to $48, and an RSI(14) of 80.1 at the 2026-08-07 close after a 22.3% three-month advance. The qualification matters — the participation evidence is thin. The label rests mostly on the price-and-headline leg, not on demonstrated flow expansion.
• Crowding observables, stated as observables: RSI(14) 80.1 is at the extreme end of its range; price is far extended above the 52-week low; the company itself remains a programmatic buyer under the $850M residual authorization; no insider transactions were verified in the sources reviewed for this note; the next company-scheduled catalyst is roughly eleven weeks out. There is no imminent earnings date compressing the move, which removes a common near-term crowding trigger and also removes the event that would refresh the story.
• Structure: the advance is a retracement of a deep drawdown, so the relevant reference is the pre-print consolidation the stock left behind on 2026-07-29 rather than a base breakout. The $40 area sits below that post-print range; a weekly close under it would mean the July print's re-rating has been fully given back.

Catalyst Calendar (next 30 days)

• 2026-08-08 to 2026-09-07: no company-scheduled event confirmed as of 2026-08-08. The window is genuinely empty; the tape carries the story unaided.
• ~2026-10-28 (est.): Q3 FY26 results. Not announced as of 2026-08-08. Q2 was reported Wednesday 2026-07-29 before the open, which is the basis for the estimate.
• ~2026-12 (est.): the repurchase program was expanded, replenished and reauthorized in December 2025; a further board action on the authorization would be the next scheduled read on capital-return intent. Unconfirmed.
• Unscheduled: any Schedule 13D/A amendment from a large holder. Nothing dated is pending.

What Would Change Our Mind

The structure that breaks first is the guide, not the chart. The entire July advance sits on an affirmed FY26 range of $1.173–$1.179B revenue and $5.15–$5.25 adjusted EPS plus management's upper-half commentary. If the Q3 print (~2026-10-28, est.) trims that revenue range, or organic growth returns below the 3.0% posted in Q2, the cash-return case loses the growth floor that makes an 8.16 forward P/E defensible rather than a value trap.

Second, the buyback is the mechanism. If the next 10-Q shows the repurchase pace decelerating materially against the just-over-6% year-to-date reduction, or the $850M residual authorization draws down more slowly, the largest identified buyer of the stock has stepped back.

Third, on price: a weekly close below $40 retraces the post-Q2 leg in full and puts the name back inside the range it occupied when Stifel published a $30 target on 2026-07-10.

The reverse also applies. A rating upgrade — Stifel off Hold, or Evercore off In-Line — rather than another target tweak would mark the coverage catching up to the price, and would argue the re-rating has room the current In-Line/Hold consensus does not reflect. A 13D amendment from a large holder would reintroduce the strategic-value question that the 2024-04-15 $80.00 proposal put on the table and that has been dormant since.

Correlation Notes

• Not an AI-capex derivative. Blackbaud's revenue is nonprofit, faith, K-12/higher-education and social-impact vertical software. Its 2026 product messaging includes an AI-assisted connected-campus partnership with Student First; the announcement date for that partnership was not confirmed in the sources reviewed here, so it is noted without a date rather than counted as a catalyst. Correlation to semiconductor and hyperscaler AI beta should be treated as low.
• Small-cap software value complex. The move since late July is characteristic of busted-multiple software repricing on capital return. Read moves in that cohort — not in high-multiple growth software — as the relevant read-across.
• End-market sensitivity is fiscal and donative, not cyclical-industrial. Nonprofit fundraising volumes and education budgets drive renewals and payment volumes; the 98.2% recurring mix means these show up in bookings and renewal commentary on the call before they appear in the revenue line.
• Rate and credit sensitivity is unquantified in this note. A repurchase-led EPS algorithm is sensitive to funding conditions, but the reviewed sources do not give a current net-debt figure, so no magnitude is asserted.